ImmunoGen, Inc.

Good morning, ladies and gentlemen, and welcome to Immunogen's third quarter 2023 financial and operating results conference call. Today's conference is being recorded. At this time, I'd like to turn the call over to Annabelle Chen, head of investor relations.

Please go ahead. Good morning, and thank you for joining today's call.

Earlier today, we issued a press release that includes a summary of our recent operating progress and third quarter financial results. This press release, a recording of this call, and an updated corporate deck can be found under the Investors and Media section of our website at Immunogen.com. With me today are Mark Ennedy, our President and CEO, Isabel Califonos, our Chief Commercial Officer, Michael Vasconcellos, our EVP of Research, Development, and Medical Affairs, and Lauren White, our CFO. During today's call, we will review recent progress for the business, our financial results, and highlight upcoming anticipated events. We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning, in the risk factor section of our most recent annual report on Form 10-K, and quarterly report on Form 10-Q, and in our other SEC filings, which are available at sec.gov and immunogen.com. With that, I'll turn the call over to Mark.